510 Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: Results From a Phase 1 Study of Bemdaneprocel
Viviane Tabar(Memorial Sloan Kettering Cancer Center), Antoine Lampron, Suneil K. Kalia(University Health Network), Harini Sarva(Cornell University), Alfonso Fasano(University of Toronto), Andrés M. Lozano(University of Toronto), Claire Henchcliffe(University of California, Irvine), Cameron Brennan(Memorial Sloan Kettering Cancer Center), Marcus Yountz, Ahmed Enayetellah, Kenny Yu(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Deep Brain Stimulation for Treatment-Resistant Depression
|Neuron|2005|4.1k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression
|Biological Psychiatry|2008|1k